Oak Hill Wealth Advisors LLC Sells 511 Shares of Pfizer Inc. $PFE

Oak Hill Wealth Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,142 shares of the biopharmaceutical company’s stock after selling 511 shares during the quarter. Oak Hill Wealth Advisors LLC’s holdings in Pfizer were worth $209,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth approximately $27,000. North Capital Inc. purchased a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Horizon Financial Services LLC purchased a new position in shares of Pfizer during the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC purchased a new position in shares of Pfizer during the first quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.1%

Pfizer stock opened at $27.37 on Friday. The business has a fifty day moving average of $24.67 and a two-hundred day moving average of $24.15. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market cap of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PFE. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday. Finally, Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.